
Pacira Pharmaceuticals (PCRX) Stock Forecast & Price Target
Pacira Pharmaceuticals (PCRX) Analyst Ratings
Bulls say
Pacira BioSciences is viewed positively because Viatris’s $36.50-per-share all-cash offer validates the company’s underappreciated commercial franchise and platform optionality while delivering a ~45% premium and ~$1.65B equity value. The deal price is supported by more than $50M of annual run-rate cost synergies, which, when capitalized, largely explains the gap above the prior standalone DCF value of about $25/sh and implies Pacira’s assets are being monetized at roughly 9.3x LTM adjusted EBITDA. Strategically, Pacira adds EXPAREL ($587M LTM revenue), ZILRETTA ($121M), a ~340-person specialty sales force, international expansion rights, and PCRX-201 gene-therapy upside, all of which strengthen the bull case despite litigation and execution risks.
Bears say
Pacira BioSciences is viewed negatively because a failed or terminated transaction could send shares back below pre-announcement levels, with the market likely penalizing the company for the negative signaling effect of a broken deal. The downside case hinges on execution and regulatory uncertainty, including failure to meet the >50% minimum tender condition, a material adverse change, or FTC/antitrust intervention, while also exposing investors to deal-mechanics risk, concentration risk, and liquidity risk. Beyond the transaction, the business still faces commercial and supply chain risk, clinical and regulatory risk, competitive pressure, partnership risk, and intellectual property and legal challenges across EXPAREL, ZILRETTA, iovera, and PCRX-201.
This aggregate rating is based on analysts' research of Pacira Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Pacira Pharmaceuticals (PCRX) Analyst Forecast & Price Prediction
Start investing in Pacira Pharmaceuticals (PCRX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Pacira Pharmaceuticals (PCRX) Forecast
Pacira Pharmaceuticals (PCRX) Analyst Forecast & Price Prediction
Start investing in Pacira Pharmaceuticals (PCRX)
Order type
Buy in
Order amount
Est. shares
0 shares